Encochleated atovaquone - Matinas BioPharma

Drug Profile

Encochleated atovaquone - Matinas BioPharma

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Matinas BioPharma; National Institute of Allergy and Infectious Diseases
  • Class Antiprotozoals; Naphthoquinones
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pneumocystis pneumonia

Most Recent Events

  • 07 Jun 2018 Pharmacodynamics and pharmacokinetics data from preclinical studies in Pneumocystis pneumonia presented at the American Society for Microbiology's Microbe 2018 (ASMM-2018)
  • 10 Oct 2015 Pharmacodynamics data from a preclinical trial in pneumocystis pneumonia released by Matinas BioPharma
  • 10 Oct 2015 Pharmacokinetics data from a preclinical trial in pneumocystis pneumonia released by Matinas BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top